India drugmakers to sell Ozempic copy for $14 a month as Novo patent expires

Indian drugmakers seized on the patent expiry for Novo Nordisk A/S’s blockbuster weight-loss and diabetes medication to roll out cut-price generic versions in a nation with the third-largest overweight population. Read More